Screener
Crinetics Pharmaceuticals CRNX Common Stock Par Value Per Share
Common Stock Par Value Per Share at other companies
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CommonStockParOrStatedValuePerShare.
The source filing: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:21 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001658247-26-000040
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Commitments and contingencies (Note 6) | ||
| STOCKHOLDERS’ EQUITY | ||
| Preferred stock, $0.001 par; 10,000 shares authorized; no shares issued or outstanding at March 31, 2026 or December 31, 2025 | — | — |
| Common stock and paid-in capital, $0.001 par; 200,000 shares authorized; 105,314 shares issued and outstanding at March 31, 2026; 95,575 shares issued and outstanding at December 31, 2025 | 2,828,204 | 2,407,757 |
| Accumulated other comprehensive (loss) income | (1,254) | 1,865 |
| Accumulated deficit | (1,545,272) | (1,417,427) |
| Stock held in trust | (1,032) | (112) |
| TOTAL STOCKHOLDERS’ EQUITY | 1,280,646 | 992,083 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Crinetics Pharmaceuticals's common stock par value per share?
- Crinetics Pharmaceuticals (CRNX) reported common stock par value per share of $0.00 in Q1 2026.
- What does common stock par value per share mean?
- The par value of common stock is the arbitrary legal value assigned to each share of common stock at the time of issuance. It is a legacy accounting requirement that has little impact on the actual market value or trading price of the shares.
Ask your AI about Crinetics Pharmaceuticals's common stock par value per share.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude